Search results for "Deep vein"

showing 10 items of 96 documents

The Impact of Venous Thromboembolism In Critically Ill Patients: A Meta-Analysis of Major Clinical outcomes

2010

Abstract Abstract 3327 Background: Critically ill patients are at high risk of developing venous thromboembolism (VTE) during their stay in the intensive care unit (ICU) because of premorbid medical and surgical conditions. The clinical consequences of Deep Vein Thrombosis (DVT) have the potential to be serious yet are frequently unrecognized in the Intensive Care Unit (ICU). In contrast to the extensive documentation on the short and long–term outcomes of patients with DVT evaluated in other clinical settings, little is known about the clinical course of this disease in the ICU setting. We hypothesized that both undetected and clinically evident VTE would affect the prognosis of critically…

Mechanical ventilationmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentDeep veinImmunologyCell BiologyHematologyBiochemistryIntensive care unitConfidence intervallaw.inventionStudy heterogeneitymedicine.anatomical_structurelawRelative riskMeta-analysisEmergency medicinemedicineVenous thrombosis metaanalysisbusinessIntensive care medicineProspective cohort study
researchProduct

COVID-19 Vaccine and Death: Causality Algorithm According to the WHO Eligibility Diagnosis

2021

The current challenge worldwide is the administration of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. Even if rarely, severe vascular adverse reactions temporally related to vaccine administration have induced diffidence in the population at large. In particular, researchers worldwide are focusing on the so-called “thrombosis and thrombocytopenia after COVID-19 vaccination”. This study aims to establish a practical workflow to define the relationship between adverse events following immunization (AEFI) and COVID-19 vaccination, following the basic framework of the World Health Organization (WHO). Post-mortem investigation plays a pivotal role to support this c…

Medicine (General)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clinical BiochemistryPopulation030204 cardiovascular system & hematologyArticledeep vein thrombosisAutoimmune thrombocytopenia03 medical and health sciencesautopsyR5-9200302 clinical medicinevaccinestandard protocolMedicineIntensive care medicineeducationAdverse effectdisseminated intravascular coagulationeducation.field_of_studySARS-CoV-2business.industryCOVID-19post-mortem investigationCausalityVaccinationimmune thrombocytopeniaImmunization030220 oncology & carcinogenesisvaccination campaignbusinessDiagnostics
researchProduct

Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow‐Up Survey

2020

Abstract Background Fundamental Research in Oncology and Thrombosis (FRONTLINE) is a global survey of physicians' perceptions and practice in the management of venous thromboembolism (VTE) in patients with cancer. Materials and Methods The present survey, FRONTLINE 2, follows the original FRONTLINE survey (published in The Oncologist in 2003) and provides insights into how physicians perceive risk of VTE in cancer and approach its prophylaxis and treatment. Results Between November 2015 and February 2016, 5,233 respondents participated, representing cancer physicians and surgeons. Most believed that less than one in five patients with any cancer might be at risk of VTE, with a slightly high…

OncologyCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatment26030204 cardiovascular system & hematologyFondaparinuxDabigatranVenous thromboembolism • Cancer-associated thrombosis • Deep vein thrombosis • Pulmonary embolism • Central venous catheter.03 medical and health sciences0302 clinical medicineInternal medicineSurveys and QuestionnairesVenous thromboembolism • Cancer‐associated thrombosis • Deep vein thrombosis • Pulmonary embolism • Central venous cathetermedicineHumansRivaroxabanbusiness.industryAnticoagulantWarfarinCancerAnticoagulantsThrombosisVenous ThromboembolismHeparin Low-Molecular-Weightmedicine.diseasePulmonary embolismOncologySymptom Management and Supportive Care030220 oncology & carcinogenesisbusinessCentral venous cathetermedicine.drugFollow-Up StudiesThe Oncologist
researchProduct

How Epidemiology of Polycythemia Vera Has Changed in the Last 10 Years: Results From the Whole Prospective Cohort of Patients in Cyto-PV Trial As Com…

2012

Abstract Abstract 1748 Introduction: Polycythemia vera (PV) is a chronic myeloproliferative neoplasms characterized by erythrocytosis, vasomotor disturbances, pruritus, risk of disease progression into acute myeloid leukemia or myelofibrosis and cardiovascular events, the last representing the main cause of morbidity and mortality. Since 2005 the V617F point mutation in Janus Kinase 2 (JAK2) gene gained a dominant role in determining the molecular basis and the diagnosis of PV. We compared the clinical epidemiology of the 1638 patients included in the ECLAP trial in the years 1997 to 2001, with that of a “modern” cohort of 365 PV, JAK2-positive patients included in the Italian CYTO-PV rando…

Pediatricsmedicine.medical_specialtyAcute coronary syndromebusiness.industryIncidence (epidemiology)Deep veinImmunologyCell BiologyHematologymedicine.diseaseBiochemistryThrombosismedicine.anatomical_structureCohortEpidemiologymedicineProspective cohort studybusinessStrokeBlood
researchProduct

Recurrent venous thromboembolism complicated by heparin-induced thrombocytopenia as a first manifestation of an occult cancer: a case report.

2008

Heparin-Induced Trombocytopenia (HIT) is a serious and potentially fatal complication of patients on heparins. Its management is difficult and it can be more complicated in patients with cancer because of the hemorrhagic risk carried out by direct inhibitor of thrombin, the currently approved drug for HIT. At present, it is not clear whether cancer patients also have an increased risk of HIT. We describe the case of a patient with occult cancer at the moment of the index venous thrombosis, who developed Deep Vein Thrombosis (DVT) and concomitant HIT with thrombotic complications (recurrent contralateral venous thrombosis). The management of HIT was efficaciously based on the combined use o…

PharmacologyFirst episodemedicine.medical_specialtybusiness.industryDeep veinImmunologyCancerDefibrotidemedicine.diseaseThrombosisVenous thrombosismedicine.anatomical_structureInternal medicineHeparin-induced thrombocytopeniaAntithromboticmedicineImmunology and Allergybusinessmedicine.drug
researchProduct

Impact of cancer on the effectiveness of cardiac Troponin I to predict right ventricular dysfunction in acute pulmonary embolism

2015

Background Deep vein thrombosis (DVT) and pulmonary embolism (PE) are connected with a poor outcome in cancer patients. We aimed to investigate the impact of cancer on the effectiveness of cardiac Troponin I (cTnI) to predict right ventricular dysfunction (RVD) in acute PE. Methods We retrospectively analyzed the data of 182 patients with confirmed PE. PE patients were subdivided into two groups: (i) with concomitant active cancer disease or history of cancer, and (ii) without known cancer. Receiver operating characteristic (ROC) curves with area under the curve (AUC) was calculated for cTnI predicting RVD and related cut-off levels for both groups. Results Thirty-seven PE patients (20.3%) …

Pulmonary and Respiratory Medicinemedicine.medical_specialtyReceiver operating characteristicbusiness.industryDeep veinArea under the curveCancerGeneral Medicinemedicine.diseaseThrombosisSurgeryPulmonary embolismmedicine.anatomical_structureOncologyConcomitantInternal medicineTroponin Icardiovascular systemmedicineCardiologybusinessThoracic Cancer
researchProduct

Inherited Thrombophilic Risk Factors and Venous Thromboembolism

2000

Study objectives To investigate whether the FIIA20210 mutation is associated with isolated pulmonaryembolism (PE). Design Case-control study. Setting Five thrombosis centers in southern Italy. Patients Six hundred forty-seven consecutive referredpatients with objectively documented venous thrombosis and 1,329control subjects. Measurements and results Medicalhistories were collected. The G-to-A transition at nucleotide 1691within the factor V gene (FV Leiden) and the G-to-A transition atnucleotide position 20210 within the prothrombin gene locus (FIIA20210), levels of anticoagulant factors, and levelsof antiphospholipid antibodies were determined by standard techniques.Patients with deep ven…

Pulmonary and Respiratory Medicinemedicine.medical_specialtybiologymedicine.drug_classbusiness.industryDeep veinAnticoagulantFactor VCritical Care and Intensive Care Medicinemedicine.diseaseGastroenterologyThrombosisSurgeryPulmonary embolismVenous thrombosismedicine.anatomical_structureInternal medicinemedicineFactor V Leidenbiology.proteinRisk factorCardiology and Cardiovascular MedicinebusinessChest
researchProduct

The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes

2015

Background. Critically ill patients appear to be at high risk of developing deep vein thrombosis (DVT) and pulmonary embolism during their stay in the intensive care unit (ICU). However, little is known about the clinical course of venous thromboembolism in the ICU setting. We therefore evaluated, through a systematic review of the literature, the available data on the impact of a diagnosis of DVT on hospital and ICU stay, duration of mechanical ventilation and mortality in critically ill patients. We also tried to determine whether currently adopted prophylactic measures need to be revised and improved in the ICU setting. Materials and methods. MEDLINE and EMBASE databases were searched up…

RiskCritical IllnessIntensive Care UnitCritically ill patients; Deep vein thrombosis; Meta-analysis; Outcomes; Cohort Studies; Hospital Mortality; Humans; Intensive Care Units; Length of Stay; Pulmonary Embolism; Randomized Controlled Trials as Topic; Research Design; Respiration Artificial; Risk; Thrombophilia; Treatment Outcome; Venous Thrombosis; Critical Illness; Hematology; Immunology and AllergyReviewDeep Vein Thrombosis Critically Ill Patients outcomes metanalysisCohort StudiesDeep vein thrombosiImmunology and AllergyHumansThrombophiliaMeta-analysiVenous ThrombosiHospital MortalityOutcomeRandomized Controlled Trials as TopicVenous ThrombosisHematologyLength of StayRespiration ArtificialIntensive Care UnitsTreatment OutcomeResearch DesignCritical IllneCritically ill patientCohort StudiePulmonary EmbolismHuman
researchProduct

Activación plaquetaria e hipercolesterolemia en la patogenia de la trombosis venosa profunda

2006

Currently it is accepted that deep vein thrombosis is a multifactorial event in which the presence of activated platelets and also plasmatic lipids seems to play a pivotal role that it is not well established in the scientific bibliography. Due to the non consensus state about these topics between the different groups working in these aspects, the topic involving deep vein thrombosis-platelets-lipids, and also their interactions, still is an interesting area of investigation, in which it is necessary to carry out studies with the aim of establishing risk factors, initial diagnostic methods and clinical assays to probe the efficacy of new therapies.

Venous thrombosisDiagnostic methodsmedicine.anatomical_structurebusiness.industryDeep veinmedicineGeneral MedicinePlatelet activationmedicine.diseaseBioinformaticsbusinessThrombosisMedicina Clínica
researchProduct

Oral Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip or Knee Arthroplasty: A Pooled Analysis of Four …

2011

Abstract Abstract 2312 Introduction: Thromboprophylaxis after major orthopaedic surgery reduces the risk of venous thromboembolism (VTE). Four randomized, double-blind, non-inferiority trials compared oral dabigatran etexilate doses of 220 mg or 150 mg once daily (qd) with subcutaneous enoxaparin for the primary prevention of VTE in patients undergoing elective total hip or knee arthroplasty. In the hip arthroplasty trials (RE-NOVATE® and RE-NOVATE® II) the treatment duration was 28–35 days; in the knee arthroplasty trials it was 6–10 days (RE-MODEL™) and 12–15 days (RE-MOBILIZE®). Three of the trials used a comparator enoxaparin regimen of 40 mg qd started the evening before surgery, while…

business.industryDeep veinmedicine.medical_treatmentImmunologyCell BiologyHematologymedicine.diseaseBiochemistryArthroplastyThrombosisPreoperative careDabigatranPulmonary embolismlaw.inventionRegimenmedicine.anatomical_structureRandomized controlled triallawAnesthesiaMedicinebusinessmedicine.drugBlood
researchProduct